Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22084416 | 0.88 | HPGD (0.38) | HPGDLMNA | |
| SCHEMBL22084694 | 0.88 | LPL (0.40) | LPLLIPGHPGDLMNA | |
| SCHEMBL22084393 | 0.85 | HPGD (0.40) | HPGDLMNA | |
| SCHEMBL22084413 | 0.84 | HPGD (0.38) | HPGDLMNA | |
| SCHEMBL22084415 | 0.83 | HPGD (0.42) | HPGDLMNA | |
| SCHEMBL22084380 | 0.82 | HPGD (0.41) | HPGD | |
| SCHEMBL22084689 | 0.82 | HPGD (0.36) | HPGDLMNA | |
| SCHEMBL22084391 | 0.81 | HPGD (0.39) | HPGDLMNA | |
| SCHEMBL22084420 | 0.81 | HPGD (0.39) | HPGDLMNA | |
| SCHEMBL22084696 | 0.81 | HPGD (0.45) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041627-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-10 | — | — | US | disclosed |
| WO-2020117938-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041627-A1 | PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF | ENPP2, PAICS, TPMT | LPL 3853/4885LIPG 1751/4885HPGD 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.